A randomised phase II trial of carboplatin and gemcitabine +/- vandetanib in first line treatment of advanced urothelial cell cancer patients not suitable to receive cisplatin
Authors
Jones, RCrabb, S
Chester, J
Elliott, Tony
Huddart, R
Birtle, A
Evans, L
Lester, J
Jagdev, S
Casbard, A
Huang, C
Madden, TA
Griffiths, G
Affiliation
University of Glasgow, Beatson West of Scotland Cancer Centre, Glasgow, UK.Issue Date
2020
Metadata
Show full item recordCitation
Jones R, Crabb S, Chester J, Elliott T, Huddart R, Birtle A, et al. A randomised Phase II trial of carboplatin and gemcitabine +/- vandetanib in first-line treatment of patients with advanced urothelial cell cancer not suitable to receive cisplatin. BJU Int. 2020.Journal
BJU InternationalDOI
10.1111/bju.15096PubMed ID
32336008Additional Links
https://dx.doi.org/ 10.1111/bju.15096Type
ArticleLanguage
enae974a485f413a2113503eed53cd6c53
10.1111/bju.15096
Scopus Count
Collections
Related articles
- Vandetanib plus gemcitabine versus placebo plus gemcitabine in locally advanced or metastatic pancreatic carcinoma (ViP): a prospective, randomised, double-blind, multicentre phase 2 trial.
- Authors: Middleton G, Palmer DH, Greenhalf W, Ghaneh P, Jackson R, Cox T, Evans A, Shaw VE, Wadsley J, Valle JW, Propper D, Wasan H, Falk S, Cunningham D, Coxon F, Ross P, Madhusudan S, Wadd N, Corrie P, Hickish T, Costello E, Campbell F, Rawcliffe C, Neoptolemos JP
- Issue date: 2017 Apr
- Intercalated combination of chemotherapy and erlotinib for patients with advanced stage non-small-cell lung cancer (FASTACT-2): a randomised, double-blind trial.
- Authors: Wu YL, Lee JS, Thongprasert S, Yu CJ, Zhang L, Ladrera G, Srimuninnimit V, Sriuranpong V, Sandoval-Tan J, Zhu Y, Liao M, Zhou C, Pan H, Lee V, Chen YM, Sun Y, Margono B, Fuerte F, Chang GC, Seetalarom K, Wang J, Cheng A, Syahruddin E, Qian X, Ho J, Kurnianda J, Liu HE, Jin K, Truman M, Bara I, Mok T
- Issue date: 2013 Jul
- Vinflunine/gemcitabine versus carboplatin/gemcitabine as first-line treatment in cisplatin-ineligible patients with advanced urothelial carcinoma: A randomised phase II trial (VINGEM).
- Authors: Holmsten K, Jensen NV, Mouritsen LS, Jonsson E, Mellnert C, Agerbæk M, Nilsson C, Moe M, Carus A, Öfverholm E, Lahdenperä O, Brandberg Y, Johansson H, Hellström M, Maase HV, Pappot H, Ullén A
- Issue date: 2020 Mar
- Maintenance therapy with vinflunine plus best supportive care versus best supportive care alone in patients with advanced urothelial carcinoma with a response after first-line chemotherapy (MAJA; SOGUG 2011/02): a multicentre, randomised, controlled, open-label, phase 2 trial.
- Authors: García-Donas J, Font A, Pérez-Valderrama B, Virizuela JA, Climent MÁ, Hernando-Polo S, Arranz JÁ, Del Mar Llorente M, Lainez N, Villa-Guzmán JC, Mellado B, González Del Alba A, Castellano D, Gallardo E, Anido U, García Del Muro X, Domènech M, Puente J, Morales-Barrera R, Pérez-Gracia JL, Bellmunt J
- Issue date: 2017 May
- Adjuvant chemotherapy in upper tract urothelial carcinoma (the POUT trial): a phase 3, open-label, randomised controlled trial.
- Authors: Birtle A, Johnson M, Chester J, Jones R, Dolling D, Bryan RT, Harris C, Winterbottom A, Blacker A, Catto JWF, Chakraborti P, Donovan JL, Elliott PA, French A, Jagdev S, Jenkins B, Keeley FX Jr, Kockelbergh R, Powles T, Wagstaff J, Wilson C, Todd R, Lewis R, Hall E
- Issue date: 2020 Apr 18